Announcements 06 December 2021

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Research UK, the world’s leading cancer charity, today announced that the first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3-expressing solid malignancies (NCT05057013).

Announcements 29 November 2021

Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the appointment of Jan Møller Mikkelsen as Chairman of its Board of Directors.

Publications & Posters 12 November 2021

Announcements 10 November 2021

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a unique anti-VISTA antibody developed using Hummingbird’s Rational Antibody Discovery platform to address VISTA-mediated suppression of anti-tumor immune responses, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The meeting will be held in Washington, D.C. and virtually from November 10 to 14, 2021.

Announcements 25 October 2021

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreement with Merck.

Announcements 07 October 2021

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the presentation of pre-clinical data on novel biomarkers for HER3-driven cancers at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021. The conference will take place from October 7 to 10, 2021.

Publications & Posters 07 October 2021

Announcements 23 September 2021

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, has opened its new office location at the Singapore Science Park. The new base strengthens its Singapore presence and complements its offices in the United States at Texas Medical Centre and South San Francisco.